DK175828B1 - CMV-relateret polypeptid, fremgangsmåde og diagnostisk system i form af et prövesæt til afprövning for anti-EBNA-antistoffer - Google Patents

Info

Publication number

DK175828B1

DK175828B1 DK199100211A DK21191A DK175828B1 DK 175828 B1 DK175828 B1 DK 175828B1 DK 199100211 A DK199100211 A DK 199100211A DK 21191 A DK21191 A DK 21191A DK 175828 B1 DK175828 B1 DK 175828B1

Authority

DK

Denmark

Prior art keywords

gly

polypeptide

antibodies

ebna

protein

Prior art date

1988-08-09

Links

• Espacenet
• Global Dossier
• Discuss

• 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 440
• 229920001184 polypeptide Polymers 0.000 title claims abstract description 406
• 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 391
• 238000000034 method Methods 0.000 title claims description 165
• 238000012360 testing method Methods 0.000 title description 79
• 208000015181 infectious disease Diseases 0.000 claims abstract description 68
• 108090000623 proteins and genes Proteins 0.000 claims description 263
• 102000004169 proteins and genes Human genes 0.000 claims description 163
• 101710167887 Major outer membrane protein P.IA Proteins 0.000 claims description 120
• 101710167885 Major outer membrane protein P.IB Proteins 0.000 claims description 93
• 239000000203 mixture Substances 0.000 claims description 66
• 239000013612 plasmid Substances 0.000 claims description 55
• 241000588652 Neisseria gonorrhoeae Species 0.000 claims description 50
• 229960005486 vaccine Drugs 0.000 claims description 48
• 239000013598 vector Substances 0.000 claims description 40
• 230000000890 antigenic effect Effects 0.000 claims description 36
• 238000004519 manufacturing process Methods 0.000 claims description 36
• 108091028043 Nucleic acid sequence Proteins 0.000 claims description 24
• 241000588724 Escherichia coli Species 0.000 claims description 20
• 125000003729 nucleotide group Chemical group 0.000 claims description 20
• 239000002773 nucleotide Substances 0.000 claims description 19
• 244000005700 microbiome Species 0.000 claims description 16
• 108020004707 nucleic acids Proteins 0.000 claims description 9
• 102000039446 nucleic acids Human genes 0.000 claims description 9
• 150000007523 nucleic acids Chemical class 0.000 claims description 9
• 241000588653 Neisseria Species 0.000 claims description 5
• 239000003298 DNA probe Substances 0.000 claims description 4
• 239000003937 drug carrier Substances 0.000 claims description 4
• 230000004048 modification Effects 0.000 claims description 4
• 238000012986 modification Methods 0.000 claims description 4
• 238000011160 research Methods 0.000 claims description 4
• 108020003215 DNA Probes Proteins 0.000 claims description 3
• 101001137313 Neisseria gonorrhoeae Major outer membrane protein P.IA Proteins 0.000 claims description 2
• 101000599279 Neisseria gonorrhoeae Major outer membrane protein P.IB Proteins 0.000 claims description 2
• 101000599283 Neisseria gonorrhoeae Major outer membrane protein P.IB Proteins 0.000 claims description 2
• 238000012258 culturing Methods 0.000 claims description 2
• 101800001072 Protein 1A Proteins 0.000 claims 1
• 108091007433 antigens Proteins 0.000 abstract description 85
• 102000036639 antigens Human genes 0.000 abstract description 85
• 239000000427 antigen Substances 0.000 abstract description 84
• 230000001154 acute effect Effects 0.000 abstract description 81
• 125000000539 amino acid group Chemical group 0.000 abstract description 61
• 201000006747 infectious mononucleosis Diseases 0.000 abstract description 56
• 238000002405 diagnostic procedure Methods 0.000 abstract description 15
• 229920005604 random copolymer Polymers 0.000 abstract description 13
• 108010008655 Epstein-Barr Virus Nuclear Antigens Proteins 0.000 abstract 2
• 235000018102 proteins Nutrition 0.000 description 154
• 210000004027 cell Anatomy 0.000 description 110
• 239000012634 fragment Substances 0.000 description 100
• 210000002966 serum Anatomy 0.000 description 89
• 108020004414 DNA Proteins 0.000 description 82
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 77
• 239000000523 sample Substances 0.000 description 74
• 239000007790 solid phase Substances 0.000 description 70
• 238000002965 ELISA Methods 0.000 description 68
• 201000010099 disease Diseases 0.000 description 67
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 67
• 241000701022 Cytomegalovirus Species 0.000 description 59
• 239000007787 solid Substances 0.000 description 48
• 239000000463 material Substances 0.000 description 46
• 239000012071 phase Substances 0.000 description 44
• 230000027455 binding Effects 0.000 description 43
• 108020003175 receptors Proteins 0.000 description 42
• 102000005962 receptors Human genes 0.000 description 42
• 239000000047 product Substances 0.000 description 40
• 239000000243 solution Substances 0.000 description 38
• 238000003556 assay Methods 0.000 description 35
• 238000006243 chemical reaction Methods 0.000 description 32
• 230000002163 immunogen Effects 0.000 description 32
• 230000036046 immunoreaction Effects 0.000 description 32
• 108010031111 EBV-encoded nuclear antigen 1 Proteins 0.000 description 31
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 31
• 108091034117 Oligonucleotide Proteins 0.000 description 31
• 230000000295 complement effect Effects 0.000 description 31
• 101150082998 pi gene Proteins 0.000 description 30
• 241000283973 Oryctolagus cuniculus Species 0.000 description 29
• 229940024606 amino acid Drugs 0.000 description 28
• 235000001014 amino acid Nutrition 0.000 description 28
• 150000001413 amino acids Chemical class 0.000 description 28
• 230000000694 effects Effects 0.000 description 28
• 238000004458 analytical method Methods 0.000 description 27
• 239000003795 chemical substances by application Substances 0.000 description 27
• 238000002360 preparation method Methods 0.000 description 27
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 26
• 150000003839 salts Chemical class 0.000 description 26
• 206010015108 Epstein-Barr virus infection Diseases 0.000 description 25
• 239000007791 liquid phase Substances 0.000 description 25
• 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 22
• 206010061306 Nasopharyngeal cancer Diseases 0.000 description 22
• 230000002788 anti-peptide Effects 0.000 description 22
• 230000014509 gene expression Effects 0.000 description 22
• 201000011216 nasopharynx carcinoma Diseases 0.000 description 22
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 21
• 239000000284 extract Substances 0.000 description 21
• 239000002953 phosphate buffered saline Substances 0.000 description 21
• 125000003275 alpha amino acid group Chemical group 0.000 description 20
• 230000007423 decrease Effects 0.000 description 20
• 229920000642 polymer Polymers 0.000 description 20
• 238000010367 cloning Methods 0.000 description 19
• 239000011159 matrix material Substances 0.000 description 19
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 18
• 230000015572 biosynthetic process Effects 0.000 description 18
• 239000000562 conjugate Substances 0.000 description 18
• 238000009396 hybridization Methods 0.000 description 18
• 102000004190 Enzymes Human genes 0.000 description 17
• 108090000790 Enzymes Proteins 0.000 description 17
• 210000003719 b-lymphocyte Anatomy 0.000 description 17
• 239000003153 chemical reaction reagent Substances 0.000 description 17
• 229940088598 enzyme Drugs 0.000 description 17
• 239000002054 inoculum Substances 0.000 description 17
• 206010011831 Cytomegalovirus infection Diseases 0.000 description 16
• 239000002585 base Substances 0.000 description 16
• 239000007788 liquid Substances 0.000 description 16
• 238000003801 milling Methods 0.000 description 16
• 230000003287 optical effect Effects 0.000 description 16
• 238000012163 sequencing technique Methods 0.000 description 16
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 15
• 239000004471 Glycine Substances 0.000 description 15
• 230000000875 corresponding effect Effects 0.000 description 15
• 238000001514 detection method Methods 0.000 description 15
• 238000010790 dilution Methods 0.000 description 15
• 239000012895 dilution Substances 0.000 description 15
• 241000196324 Embryophyta Species 0.000 description 14
• 239000000872 buffer Substances 0.000 description 14
• 238000010276 construction Methods 0.000 description 14
• 239000000499 gel Substances 0.000 description 14
• 239000012528 membrane Substances 0.000 description 14
• 230000004044 response Effects 0.000 description 14
• 108091008146 restriction endonucleases Proteins 0.000 description 14
• 239000011780 sodium chloride Substances 0.000 description 14
• 238000003786 synthesis reaction Methods 0.000 description 14
• 229960003767 alanine Drugs 0.000 description 13
• 229940098773 bovine serum albumin Drugs 0.000 description 13
• 230000036039 immunity Effects 0.000 description 13
• 238000002955 isolation Methods 0.000 description 13
• 241000283707 Capra Species 0.000 description 12
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
• 241000700605 Viruses Species 0.000 description 12
• 238000010166 immunofluorescence Methods 0.000 description 12
• 238000001114 immunoprecipitation Methods 0.000 description 12
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 12
• 241001465754 Metazoa Species 0.000 description 11
• 239000000020 Nitrocellulose Substances 0.000 description 11
• 239000003618 borate buffered saline Substances 0.000 description 11
• 108020001507 fusion proteins Proteins 0.000 description 11
• 102000037865 fusion proteins Human genes 0.000 description 11
• 230000006872 improvement Effects 0.000 description 11
• 230000005764 inhibitory process Effects 0.000 description 11
• 239000002609 medium Substances 0.000 description 11
• 229920001220 nitrocellulos Polymers 0.000 description 11
• 230000001681 protective effect Effects 0.000 description 11
• 206010018612 Gonorrhoea Diseases 0.000 description 10
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 10
• 108010076504 Protein Sorting Signals Proteins 0.000 description 10
• 238000002105 Southern blotting Methods 0.000 description 10
• 238000007792 addition Methods 0.000 description 10
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 10
• 238000011161 development Methods 0.000 description 10
• 238000003745 diagnosis Methods 0.000 description 10
• 208000001786 gonorrhea Diseases 0.000 description 10
• 230000012010 growth Effects 0.000 description 10
• 238000011534 incubation Methods 0.000 description 10
• 238000003780 insertion Methods 0.000 description 10
• 230000037431 insertion Effects 0.000 description 10
• 238000000465 moulding Methods 0.000 description 10
• 230000009466 transformation Effects 0.000 description 10
• 230000007704 transition Effects 0.000 description 10
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 9
• 108060003951 Immunoglobulin Proteins 0.000 description 9
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 9
• 206010028980 Neoplasm Diseases 0.000 description 9
• 238000010521 absorption reaction Methods 0.000 description 9
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 9
• 230000028993 immune response Effects 0.000 description 9
• 102000018358 immunoglobulin Human genes 0.000 description 9
• 229920003023 plastic Polymers 0.000 description 9
• 239000004033 plastic Substances 0.000 description 9
• 239000013641 positive control Substances 0.000 description 9
• 230000008569 process Effects 0.000 description 9
• 230000009257 reactivity Effects 0.000 description 9
• 238000011084 recovery Methods 0.000 description 9
• 206010039073 rheumatoid arthritis Diseases 0.000 description 9
• 238000005406 washing Methods 0.000 description 9
• 101710190786 PI protein Proteins 0.000 description 8
• 108020004511 Recombinant DNA Proteins 0.000 description 8
• 235000004279 alanine Nutrition 0.000 description 8
• 210000004369 blood Anatomy 0.000 description 8
• 239000008280 blood Substances 0.000 description 8
• 201000011510 cancer Diseases 0.000 description 8
• 238000000978 circular dichroism spectroscopy Methods 0.000 description 8
• 238000002156 mixing Methods 0.000 description 8
• 238000000746 purification Methods 0.000 description 8
• -1 rhodamine B isothiocyanate Chemical class 0.000 description 8
• 239000000126 substance Substances 0.000 description 8
• 208000024891 symptom Diseases 0.000 description 8
• 238000011282 treatment Methods 0.000 description 8
• 241001529453 unidentified herpesvirus Species 0.000 description 8
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 7
• 102100034613 Annexin A2 Human genes 0.000 description 7
• 108090000668 Annexin A2 Proteins 0.000 description 7
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 7
• 230000002391 anti-complement effect Effects 0.000 description 7
• 108010008730 anticomplement Proteins 0.000 description 7
• 230000001580 bacterial effect Effects 0.000 description 7
• 230000008901 benefit Effects 0.000 description 7
• 102000005936 beta-Galactosidase Human genes 0.000 description 7
• 108010005774 beta-Galactosidase Proteins 0.000 description 7
• 230000008859 change Effects 0.000 description 7
• 239000013599 cloning vector Substances 0.000 description 7
• 238000005516 engineering process Methods 0.000 description 7
• 230000003053 immunization Effects 0.000 description 7
• 210000003296 saliva Anatomy 0.000 description 7
• 125000006850 spacer group Chemical group 0.000 description 7
• 239000000758 substrate Substances 0.000 description 7
• 238000013519 translation Methods 0.000 description 7
• 230000014616 translation Effects 0.000 description 7
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 6
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 6
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 6
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
• 108020005187 Oligonucleotide Probes Proteins 0.000 description 6
• 239000004793 Polystyrene Substances 0.000 description 6
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
• 210000001744 T-lymphocyte Anatomy 0.000 description 6
• 239000002671 adjuvant Substances 0.000 description 6
• 210000004899 c-terminal region Anatomy 0.000 description 6
• 239000000969 carrier Substances 0.000 description 6
• 230000029087 digestion Effects 0.000 description 6
• 210000004408 hybridoma Anatomy 0.000 description 6
• 238000002649 immunization Methods 0.000 description 6
• 230000016784 immunoglobulin production Effects 0.000 description 6
• 210000004698 lymphocyte Anatomy 0.000 description 6
• 239000000178 monomer Substances 0.000 description 6
• 239000002751 oligonucleotide probe Substances 0.000 description 6
• YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 6
• 210000002381 plasma Anatomy 0.000 description 6
• 229920002223 polystyrene Polymers 0.000 description 6
• 238000003127 radioimmunoassay Methods 0.000 description 6
• 239000011347 resin Substances 0.000 description 6
• 229920005989 resin Polymers 0.000 description 6
• 230000000405 serological effect Effects 0.000 description 6
• 238000010532 solid phase synthesis reaction Methods 0.000 description 6
• 238000013518 transcription Methods 0.000 description 6
• 230000035897 transcription Effects 0.000 description 6
• 108091026890 Coding region Proteins 0.000 description 5
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 5
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
• 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 5
• 229960005261 aspartic acid Drugs 0.000 description 5
• 210000000234 capsid Anatomy 0.000 description 5
• 238000005859 coupling reaction Methods 0.000 description 5
• ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 5
• 238000013461 design Methods 0.000 description 5
• 239000003085 diluting agent Substances 0.000 description 5
• 239000000975 dye Substances 0.000 description 5
• 239000013604 expression vector Substances 0.000 description 5
• 239000012530 fluid Substances 0.000 description 5
• 230000001900 immune effect Effects 0.000 description 5
• 238000003018 immunoassay Methods 0.000 description 5
• 238000000338 in vitro Methods 0.000 description 5
• 230000002401 inhibitory effect Effects 0.000 description 5
• 235000013336 milk Nutrition 0.000 description 5
• 239000008267 milk Substances 0.000 description 5
• 210000004080 milk Anatomy 0.000 description 5
• 238000006386 neutralization reaction Methods 0.000 description 5
• 230000009871 nonspecific binding Effects 0.000 description 5
• 230000001717 pathogenic effect Effects 0.000 description 5
• 230000000717 retained effect Effects 0.000 description 5
• 229960001153 serine Drugs 0.000 description 5
• 230000011664 signaling Effects 0.000 description 5
• 238000001228 spectrum Methods 0.000 description 5
• 238000010186 staining Methods 0.000 description 5
• 239000010902 straw Substances 0.000 description 5
• 238000010998 test method Methods 0.000 description 5
• 230000001225 therapeutic effect Effects 0.000 description 5
• 238000012546 transfer Methods 0.000 description 5
• 238000001262 western blot Methods 0.000 description 5
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
• 239000004475 Arginine Substances 0.000 description 4
• 206010003445 Ascites Diseases 0.000 description 4
• 241000894006 Bacteria Species 0.000 description 4
• 102000053602 DNA Human genes 0.000 description 4
• 238000012286 ELISA Assay Methods 0.000 description 4
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
• 239000004472 Lysine Substances 0.000 description 4
• 102000018721 Macroglobulins Human genes 0.000 description 4
• 108010091934 Macroglobulins Proteins 0.000 description 4
• 241000699666 Mus <mouse, genus> Species 0.000 description 4
• 206010035226 Plasma cell myeloma Diseases 0.000 description 4
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
• 239000007983 Tris buffer Substances 0.000 description 4
• 239000004480 active ingredient Substances 0.000 description 4
• 239000011543 agarose gel Substances 0.000 description 4
• ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 4
• 230000003321 amplification Effects 0.000 description 4
• RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 4
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
• 235000009697 arginine Nutrition 0.000 description 4
• 235000003704 aspartic acid Nutrition 0.000 description 4
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 4
• 230000003115 biocidal effect Effects 0.000 description 4
• 238000003776 cleavage reaction Methods 0.000 description 4
• 150000001875 compounds Chemical class 0.000 description 4
• 230000002596 correlated effect Effects 0.000 description 4
• 230000008878 coupling Effects 0.000 description 4
• 238000010168 coupling process Methods 0.000 description 4
• 239000005546 dideoxynucleotide Substances 0.000 description 4
• VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 4
• 238000009472 formulation Methods 0.000 description 4
• 230000002068 genetic effect Effects 0.000 description 4
• 229960002989 glutamic acid Drugs 0.000 description 4
• 229920001519 homopolymer Polymers 0.000 description 4
• 210000000987 immune system Anatomy 0.000 description 4
• 238000002372 labelling Methods 0.000 description 4
• 125000005647 linker group Chemical group 0.000 description 4
• 239000011777 magnesium Substances 0.000 description 4
• 201000000050 myeloid neoplasm Diseases 0.000 description 4
• 238000003199 nucleic acid amplification method Methods 0.000 description 4
• 239000000843 powder Substances 0.000 description 4
• 230000002265 prevention Effects 0.000 description 4
• 230000007017 scission Effects 0.000 description 4
• 230000035945 sensitivity Effects 0.000 description 4
• 235000004400 serine Nutrition 0.000 description 4
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
• 239000002904 solvent Substances 0.000 description 4
• 230000004936 stimulating effect Effects 0.000 description 4
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
• 230000000007 visual effect Effects 0.000 description 4
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
• GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 3
• WAAXYLYXYLKHJZ-UHFFFAOYSA-N 1-[3-(1-hydroxy-2,5-dioxopyrrolidine-3-carbonyl)phenyl]pyrrole-2,5-dione Chemical compound O=C1N(O)C(=O)CC1C(=O)C1=CC=CC(N2C(C=CC2=O)=O)=C1 WAAXYLYXYLKHJZ-UHFFFAOYSA-N 0.000 description 3
• HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 3
• 108700028369 Alleles Proteins 0.000 description 3
• 208000011691 Burkitt lymphomas Diseases 0.000 description 3
• 108700010070 Codon Usage Proteins 0.000 description 3
• 102000012410 DNA Ligases Human genes 0.000 description 3
• 108010061982 DNA Ligases Proteins 0.000 description 3
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
• 201000003066 Diffuse Scleroderma Diseases 0.000 description 3
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
• 241000701867 Enterobacteria phage T7 Species 0.000 description 3
• 108090000288 Glycoproteins Proteins 0.000 description 3
• 102000003886 Glycoproteins Human genes 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
• LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 3
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
• 208000030289 Lymphoproliferative disease Diseases 0.000 description 3
• 241000124008 Mammalia Species 0.000 description 3
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
• 108010013381 Porins Proteins 0.000 description 3
• 102000017033 Porins Human genes 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 201000009594 Systemic Scleroderma Diseases 0.000 description 3
• 206010042953 Systemic sclerosis Diseases 0.000 description 3
• 239000004473 Threonine Substances 0.000 description 3
• 239000011149 active material Substances 0.000 description 3
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
• 230000002238 attenuated effect Effects 0.000 description 3
• 230000000903 blocking effect Effects 0.000 description 3
• 239000011575 calcium Substances 0.000 description 3
• 230000001276 controlling effect Effects 0.000 description 3
• 235000018417 cysteine Nutrition 0.000 description 3
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
• 230000001419 dependent effect Effects 0.000 description 3
• 229940079593 drug Drugs 0.000 description 3
• 239000003814 drug Substances 0.000 description 3
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
• ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 3
• 230000006870 function Effects 0.000 description 3
• 238000007429 general method Methods 0.000 description 3
• 238000010353 genetic engineering Methods 0.000 description 3
• 239000011521 glass Substances 0.000 description 3
• 235000013922 glutamic acid Nutrition 0.000 description 3
• 239000004220 glutamic acid Substances 0.000 description 3
• 230000002209 hydrophobic effect Effects 0.000 description 3
• 238000002169 hydrotherapy Methods 0.000 description 3
• 230000001965 increasing effect Effects 0.000 description 3
• 230000002458 infectious effect Effects 0.000 description 3
• 239000004615 ingredient Substances 0.000 description 3
• 238000011081 inoculation Methods 0.000 description 3
• 230000003993 interaction Effects 0.000 description 3
• 231100000518 lethal Toxicity 0.000 description 3
• 230000001665 lethal effect Effects 0.000 description 3
• 235000018977 lysine Nutrition 0.000 description 3
• 229910001629 magnesium chloride Inorganic materials 0.000 description 3
• 230000003278 mimic effect Effects 0.000 description 3
• 238000002703 mutagenesis Methods 0.000 description 3
• 231100000350 mutagenesis Toxicity 0.000 description 3
• 210000004940 nucleus Anatomy 0.000 description 3
• 230000036961 partial effect Effects 0.000 description 3
• 239000002245 particle Substances 0.000 description 3
• 210000005259 peripheral blood Anatomy 0.000 description 3
• 239000011886 peripheral blood Substances 0.000 description 3
• 229960005190 phenylalanine Drugs 0.000 description 3
• 239000013600 plasmid vector Substances 0.000 description 3
• 229920002401 polyacrylamide Polymers 0.000 description 3
• 229920000136 polysorbate Polymers 0.000 description 3
• 230000010076 replication Effects 0.000 description 3
• 238000000926 separation method Methods 0.000 description 3
• 230000000638 stimulation Effects 0.000 description 3
• 230000009885 systemic effect Effects 0.000 description 3
• 229960002898 threonine Drugs 0.000 description 3
• 210000001519 tissue Anatomy 0.000 description 3
• 229960004441 tyrosine Drugs 0.000 description 3
• 230000003612 virological effect Effects 0.000 description 3
• OBYNJKLOYWCXEP-UHFFFAOYSA-N 2-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]-4-isothiocyanatobenzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(N=C=S)=CC=C1C([O-])=O OBYNJKLOYWCXEP-UHFFFAOYSA-N 0.000 description 2
• XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 2
• 208000030090 Acute Disease Diseases 0.000 description 2
• 229920001817 Agar Polymers 0.000 description 2
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
• 208000023275 Autoimmune disease Diseases 0.000 description 2
• 101150076489 B gene Proteins 0.000 description 2
• BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• 101710132601 Capsid protein Proteins 0.000 description 2
• 241001193938 Cavia magna Species 0.000 description 2
• 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
• 108020004705 Codon Proteins 0.000 description 2
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
• 241000283073 Equus caballus Species 0.000 description 2
• 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 2
• 241001131785 Escherichia coli HB101 Species 0.000 description 2
• KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
• 239000004366 Glucose oxidase Substances 0.000 description 2
• 108010015776 Glucose oxidase Proteins 0.000 description 2
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
• 108091006905 Human Serum Albumin Proteins 0.000 description 2
• 102000008100 Human Serum Albumin Human genes 0.000 description 2
• 241000701024 Human betaherpesvirus 5 Species 0.000 description 2
• ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
• 229930182816 L-glutamine Natural products 0.000 description 2
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
• 201000005505 Measles Diseases 0.000 description 2
• LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical group SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 2
• 241000699670 Mus sp. Species 0.000 description 2
• KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
• 108700028353 OmpC Proteins 0.000 description 2
• 108700006385 OmpF Proteins 0.000 description 2
• 108700022034 Opsonin Proteins Proteins 0.000 description 2
• 102000003992 Peroxidases Human genes 0.000 description 2
• 208000000474 Poliomyelitis Diseases 0.000 description 2
• 239000004365 Protease Substances 0.000 description 2
• 108020004682 Single-Stranded DNA Proteins 0.000 description 2
• 208000021386 Sjogren Syndrome Diseases 0.000 description 2
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• 239000002253 acid Substances 0.000 description 2
• 239000013543 active substance Substances 0.000 description 2
• 239000008272 agar Substances 0.000 description 2
• 108010076324 alanyl-glycyl-glycine Proteins 0.000 description 2
• 229910001870 ammonium persulfate Inorganic materials 0.000 description 2
• 150000003863 ammonium salts Chemical class 0.000 description 2
• 230000000844 anti-bacterial effect Effects 0.000 description 2
• 239000012736 aqueous medium Substances 0.000 description 2
• 229960001230 asparagine Drugs 0.000 description 2
• 235000009582 asparagine Nutrition 0.000 description 2
• 238000000376 autoradiography Methods 0.000 description 2
• 239000013602 bacteriophage vector Substances 0.000 description 2
• 230000037396 body weight Effects 0.000 description 2
• 229910021538 borax Inorganic materials 0.000 description 2
• UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
• 150000001718 carbodiimides Chemical class 0.000 description 2
• 101150055766 cat gene Proteins 0.000 description 2
• 238000004113 cell culture Methods 0.000 description 2
• 210000000170 cell membrane Anatomy 0.000 description 2
• 210000002421 cell wall Anatomy 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 239000007795 chemical reaction product Substances 0.000 description 2
• 238000001142 circular dichroism spectrum Methods 0.000 description 2
• 238000004140 cleaning Methods 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 210000001072 colon Anatomy 0.000 description 2
• 239000003086 colorant Substances 0.000 description 2
• 230000002860 competitive effect Effects 0.000 description 2
• 230000021615 conjugation Effects 0.000 description 2
• 238000011109 contamination Methods 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 229920001577 copolymer Polymers 0.000 description 2
• 230000009260 cross reactivity Effects 0.000 description 2
• 229960003067 cystine Drugs 0.000 description 2
• 231100000433 cytotoxic Toxicity 0.000 description 2
• 230000001472 cytotoxic effect Effects 0.000 description 2
• 238000000354 decomposition reaction Methods 0.000 description 2
• 230000003111 delayed effect Effects 0.000 description 2
• 238000012217 deletion Methods 0.000 description 2
• 230000037430 deletion Effects 0.000 description 2
• 238000012631 diagnostic technique Methods 0.000 description 2
• 238000010586 diagram Methods 0.000 description 2
• BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 2
• 239000000428 dust Substances 0.000 description 2
• 238000001962 electrophoresis Methods 0.000 description 2
• 238000004945 emulsification Methods 0.000 description 2
• 239000002158 endotoxin Substances 0.000 description 2
• 238000006911 enzymatic reaction Methods 0.000 description 2
• 210000003743 erythrocyte Anatomy 0.000 description 2
• 150000002148 esters Chemical group 0.000 description 2
• DUYAAUVXQSMXQP-UHFFFAOYSA-N ethanethioic S-acid Chemical compound CC(S)=O DUYAAUVXQSMXQP-UHFFFAOYSA-N 0.000 description 2
• 239000012894 fetal calf serum Substances 0.000 description 2
• 210000002950 fibroblast Anatomy 0.000 description 2
• 238000000799 fluorescence microscopy Methods 0.000 description 2
• 238000013467 fragmentation Methods 0.000 description 2
• 238000006062 fragmentation reaction Methods 0.000 description 2
• 230000004927 fusion Effects 0.000 description 2
• 238000012812 general test Methods 0.000 description 2
• 229940116332 glucose oxidase Drugs 0.000 description 2
• 235000019420 glucose oxidase Nutrition 0.000 description 2
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
• 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
• 229960002885 histidine Drugs 0.000 description 2
• 229910000040 hydrogen fluoride Inorganic materials 0.000 description 2
• 230000005847 immunogenicity Effects 0.000 description 2
• 238000012744 immunostaining Methods 0.000 description 2
• 238000002650 immunosuppressive therapy Methods 0.000 description 2
• 239000012535 impurity Substances 0.000 description 2
• 238000007373 indentation Methods 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 229960000310 isoleucine Drugs 0.000 description 2
• 210000003734 kidney Anatomy 0.000 description 2
• 101150066555 lacZ gene Proteins 0.000 description 2
• 229920006008 lipopolysaccharide Polymers 0.000 description 2
• 238000011068 loading method Methods 0.000 description 2
• 229910052749 magnesium Inorganic materials 0.000 description 2
• 238000012423 maintenance Methods 0.000 description 2
• 230000003211 malignant effect Effects 0.000 description 2
• 210000004962 mammalian cell Anatomy 0.000 description 2
• 238000013507 mapping Methods 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• 108020004999 messenger RNA Proteins 0.000 description 2
• UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
• 239000013642 negative control Substances 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 239000005022 packaging material Substances 0.000 description 2
• 244000052769 pathogen Species 0.000 description 2
• 230000008506 pathogenesis Effects 0.000 description 2
• 230000000149 penetrating effect Effects 0.000 description 2
• 238000010647 peptide synthesis reaction Methods 0.000 description 2
• 108040007629 peroxidase activity proteins Proteins 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
• 235000008729 phenylalanine Nutrition 0.000 description 2
• 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
• 239000004800 polyvinyl chloride Substances 0.000 description 2
• 229920000915 polyvinyl chloride Polymers 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 125000006239 protecting group Chemical group 0.000 description 2
• 230000017854 proteolysis Effects 0.000 description 2
• 239000012858 resilient material Substances 0.000 description 2
• 239000012723 sample buffer Substances 0.000 description 2
• 239000004576 sand Substances 0.000 description 2
• 238000012216 screening Methods 0.000 description 2
• 238000010517 secondary reaction Methods 0.000 description 2
• 238000009589 serological test Methods 0.000 description 2
• FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 2
• 229940048086 sodium pyrophosphate Drugs 0.000 description 2
• 235000010339 sodium tetraborate Nutrition 0.000 description 2
• 239000002689 soil Substances 0.000 description 2
• 238000000527 sonication Methods 0.000 description 2
• 238000001179 sorption measurement Methods 0.000 description 2
• 241000894007 species Species 0.000 description 2
• ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
• 210000000952 spleen Anatomy 0.000 description 2
• 239000013589 supplement Substances 0.000 description 2
• 230000001629 suppression Effects 0.000 description 2
• 230000002194 synthesizing effect Effects 0.000 description 2
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
• 235000019818 tetrasodium diphosphate Nutrition 0.000 description 2
• 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 2
• 238000002560 therapeutic procedure Methods 0.000 description 2
• 235000008521 threonine Nutrition 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 230000001052 transient effect Effects 0.000 description 2
• 230000017105 transposition Effects 0.000 description 2
• BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 2
• 229960004799 tryptophan Drugs 0.000 description 2
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
• 235000002374 tyrosine Nutrition 0.000 description 2
• 238000002255 vaccination Methods 0.000 description 2
• 229960004295 valine Drugs 0.000 description 2
• 238000012795 verification Methods 0.000 description 2
• 230000009447 viral pathogenesis Effects 0.000 description 2
• 230000001018 virulence Effects 0.000 description 2
• 239000012130 whole-cell lysate Substances 0.000 description 2
• OCUSNPIJIZCRSZ-ZTZWCFDHSA-N (2s)-2-amino-3-methylbutanoic acid;(2s)-2-amino-4-methylpentanoic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound CC(C)[C@H](N)C(O)=O.CC[C@H](C)[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O OCUSNPIJIZCRSZ-ZTZWCFDHSA-N 0.000 description 1
• LDVVMCZRFWMZSG-OLQVQODUSA-N (3ar,7as)-2-(trichloromethylsulfanyl)-3a,4,7,7a-tetrahydroisoindole-1,3-dione Chemical compound C1C=CC[C@H]2C(=O)N(SC(Cl)(Cl)Cl)C(=O)[C@H]21 LDVVMCZRFWMZSG-OLQVQODUSA-N 0.000 description 1
• QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 1
• ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
• LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
• 108020004465 16S ribosomal RNA Proteins 0.000 description 1
• OAKPWEUQDVLTCN-NKWVEPMBSA-N 2',3'-Dideoxyadenosine-5-triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO[P@@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)O1 OAKPWEUQDVLTCN-NKWVEPMBSA-N 0.000 description 1
• XJFPXLWGZWAWRQ-UHFFFAOYSA-N 2-[[2-[[2-[[2-[[2-[(2-azaniumylacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]acetyl]amino]acetate Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(O)=O XJFPXLWGZWAWRQ-UHFFFAOYSA-N 0.000 description 1
• FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
• 101150066375 35 gene Proteins 0.000 description 1
• YSCNMFDFYJUPEF-OWOJBTEDSA-N 4,4'-diisothiocyano-trans-stilbene-2,2'-disulfonic acid Chemical compound OS(=O)(=O)C1=CC(N=C=S)=CC=C1\C=C\C1=CC=C(N=C=S)C=C1S(O)(=O)=O YSCNMFDFYJUPEF-OWOJBTEDSA-N 0.000 description 1
• YSCNMFDFYJUPEF-UHFFFAOYSA-N 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid Chemical compound OS(=O)(=O)C1=CC(N=C=S)=CC=C1C=CC1=CC=C(N=C=S)C=C1S(O)(=O)=O YSCNMFDFYJUPEF-UHFFFAOYSA-N 0.000 description 1
• BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
• IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 1
• PCFGFYKGPMQDBX-FEKONODYSA-N 78355-50-7 Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 PCFGFYKGPMQDBX-FEKONODYSA-N 0.000 description 1
• 208000030507 AIDS Diseases 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
• 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
• ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
• 206010067484 Adverse reaction Diseases 0.000 description 1
• 229920000936 Agarose Polymers 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
• 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
• 244000144725 Amygdalus communis Species 0.000 description 1
• OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 description 1
• MUXONAMCEUBVGA-DCAQKATOSA-N Arg-Arg-Gln Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(O)=O MUXONAMCEUBVGA-DCAQKATOSA-N 0.000 description 1
• RKXVTTIQNKPCHU-KKHAAJSZSA-N Asp-Val-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC(O)=O RKXVTTIQNKPCHU-KKHAAJSZSA-N 0.000 description 1
• 241000972773 Aulopiformes Species 0.000 description 1
• 208000003950 B-cell lymphoma Diseases 0.000 description 1
• 231100000699 Bacterial toxin Toxicity 0.000 description 1
• OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical group C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• 239000005745 Captan Substances 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• 108010078791 Carrier Proteins Proteins 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 201000006082 Chickenpox Diseases 0.000 description 1
• 206010008631 Cholera Diseases 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• 208000032170 Congenital Abnormalities Diseases 0.000 description 1
• 206010010356 Congenital anomaly Diseases 0.000 description 1
• 241000724252 Cucumber mosaic virus Species 0.000 description 1
• CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
• WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 1
• 229930182847 D-glutamic acid Natural products 0.000 description 1
• KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
• 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 1
• 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
• 230000007023 DNA restriction-modification system Effects 0.000 description 1
• 102000016911 Deoxyribonucleases Human genes 0.000 description 1
• 108010053770 Deoxyribonucleases Proteins 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
• 238000003072 Ellman's test Methods 0.000 description 1
• 101710147543 Epstein-Barr nuclear antigen leader protein Proteins 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 108060002716 Exonuclease Proteins 0.000 description 1
• 108010022355 Fibroins Proteins 0.000 description 1
• 229920001917 Ficoll Polymers 0.000 description 1
• 241000724791 Filamentous phage Species 0.000 description 1
• 108010000916 Fimbriae Proteins Proteins 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
• 102000002464 Galactosidases Human genes 0.000 description 1
• 108010093031 Galactosidases Proteins 0.000 description 1
• GFLQTABMFBXRIY-GUBZILKMSA-N Glu-Gln-Arg Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GFLQTABMFBXRIY-GUBZILKMSA-N 0.000 description 1
• XHWLNISLUFEWNS-CIUDSAMLSA-N Glu-Gln-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O XHWLNISLUFEWNS-CIUDSAMLSA-N 0.000 description 1
• 101150016456 Hexa gene Proteins 0.000 description 1
• TXLQHACKRLWYCM-DCAQKATOSA-N His-Glu-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O TXLQHACKRLWYCM-DCAQKATOSA-N 0.000 description 1
• 108090000144 Human Proteins Proteins 0.000 description 1
• 102000003839 Human Proteins Human genes 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• DBXXASNNDTXOLU-MXAVVETBSA-N Ile-Leu-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N DBXXASNNDTXOLU-MXAVVETBSA-N 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 241000274177 Juniperus sabina Species 0.000 description 1
• QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
• CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
• 235000019766 L-Lysine Nutrition 0.000 description 1
• FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• 239000004201 L-cysteine Substances 0.000 description 1
• 235000013878 L-cysteine Nutrition 0.000 description 1
• 229930182844 L-isoleucine Natural products 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• 229930195722 L-methionine Natural products 0.000 description 1
• 229930182821 L-proline Natural products 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• 206010025280 Lymphocytosis Diseases 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• 101710175243 Major antigen Proteins 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• OSOLWRWQADPDIQ-DCAQKATOSA-N Met-Asp-Leu Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O OSOLWRWQADPDIQ-DCAQKATOSA-N 0.000 description 1
• 238000006845 Michael addition reaction Methods 0.000 description 1
• 101100107555 Mus musculus Aarsd1 gene Proteins 0.000 description 1
• 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
• 108010051791 Nuclear Antigens Proteins 0.000 description 1
• 102000019040 Nuclear Antigens Human genes 0.000 description 1
• 108700026244 Open Reading Frames Proteins 0.000 description 1
• 208000001388 Opportunistic Infections Diseases 0.000 description 1
• 208000012868 Overgrowth Diseases 0.000 description 1
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
• 101800000212 P1A protein Proteins 0.000 description 1
• 101150032327 PI3 gene Proteins 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 241000609499 Palicourea Species 0.000 description 1
• 108090000526 Papain Proteins 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 102000057297 Pepsin A Human genes 0.000 description 1
• 108090000284 Pepsin A Proteins 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108010033276 Peptide Fragments Proteins 0.000 description 1
• 102000007079 Peptide Fragments Human genes 0.000 description 1
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
• 239000004698 Polyethylene Substances 0.000 description 1
• 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 239000004353 Polyethylene glycol 8000 Substances 0.000 description 1
• 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
• 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
• 239000004743 Polypropylene Substances 0.000 description 1
• 229920001213 Polysorbate 20 Polymers 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• VPVHXWGPALPDGP-GUBZILKMSA-N Pro-Asn-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O VPVHXWGPALPDGP-GUBZILKMSA-N 0.000 description 1
• GZNYIXWOIUFLGO-ZJDVBMNYSA-N Pro-Thr-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GZNYIXWOIUFLGO-ZJDVBMNYSA-N 0.000 description 1
• 108010001267 Protein Subunits Proteins 0.000 description 1
• 102000002067 Protein Subunits Human genes 0.000 description 1
• 206010037660 Pyrexia Diseases 0.000 description 1
• 108020004518 RNA Probes Proteins 0.000 description 1
• 239000003391 RNA probe Substances 0.000 description 1
• 239000012980 RPMI-1640 medium Substances 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
• 108700008625 Reporter Genes Proteins 0.000 description 1
• 108010005173 SERPIN-B5 Proteins 0.000 description 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
• 229920005654 Sephadex Polymers 0.000 description 1
• 239000012507 Sephadex™ Substances 0.000 description 1
• SRTCFKGBYBZRHA-ACZMJKKPSA-N Ser-Ala-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O SRTCFKGBYBZRHA-ACZMJKKPSA-N 0.000 description 1
• BTKUIVBNGBFTTP-WHFBIAKZSA-N Ser-Ala-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(O)=O BTKUIVBNGBFTTP-WHFBIAKZSA-N 0.000 description 1
• WOUIMBGNEUWXQG-VKHMYHEASA-N Ser-Gly Chemical compound OC[C@H](N)C(=O)NCC(O)=O WOUIMBGNEUWXQG-VKHMYHEASA-N 0.000 description 1
• 206010041509 Spherocytic anaemia Diseases 0.000 description 1
• 206010041660 Splenomegaly Diseases 0.000 description 1
• 241000191967 Staphylococcus aureus Species 0.000 description 1
• 108091081024 Start codon Proteins 0.000 description 1
• 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
• 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 101100328546 Sus scrofa C3 gene Proteins 0.000 description 1
• 108010008038 Synthetic Vaccines Proteins 0.000 description 1
• 230000024932 T cell mediated immunity Effects 0.000 description 1
• 230000005867 T cell response Effects 0.000 description 1
• 206010043376 Tetanus Diseases 0.000 description 1
• 239000004098 Tetracycline Substances 0.000 description 1
• WYLAVUAWOUVUCA-XVSYOHENSA-N Thr-Phe-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O WYLAVUAWOUVUCA-XVSYOHENSA-N 0.000 description 1
• 102000009843 Thyroglobulin Human genes 0.000 description 1
• 108010034949 Thyroglobulin Proteins 0.000 description 1
• 102000008579 Transposases Human genes 0.000 description 1
• 108010020764 Transposases Proteins 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• 108700009899 Type 1 Spherocytosis Proteins 0.000 description 1
• 208000037386 Typhoid Diseases 0.000 description 1
• MQUYPYFPHIPVHJ-MNSWYVGCSA-N Tyr-Trp-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC3=CC=C(C=C3)O)N)O MQUYPYFPHIPVHJ-MNSWYVGCSA-N 0.000 description 1
• GXAZTLJYINLMJL-LAEOZQHASA-N Val-Asn-Gln Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N GXAZTLJYINLMJL-LAEOZQHASA-N 0.000 description 1
• RTJPAGFXOWEBAI-SRVKXCTJSA-N Val-Val-Arg Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N RTJPAGFXOWEBAI-SRVKXCTJSA-N 0.000 description 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
• 206010046980 Varicella Diseases 0.000 description 1
• 241000700647 Variola virus Species 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 108010067390 Viral Proteins Proteins 0.000 description 1
• HDRRAMINWIWTNU-NTSWFWBYSA-N [[(2s,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1CC[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HDRRAMINWIWTNU-NTSWFWBYSA-N 0.000 description 1
• ARLKCWCREKRROD-POYBYMJQSA-N [[(2s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)CC1 ARLKCWCREKRROD-POYBYMJQSA-N 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 229940022663 acetate Drugs 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 239000008186 active pharmaceutical agent Substances 0.000 description 1
• 125000002252 acyl group Chemical group 0.000 description 1
• 230000006978 adaptation Effects 0.000 description 1
• 230000001464 adherent effect Effects 0.000 description 1
• 238000004026 adhesive bonding Methods 0.000 description 1
• 239000012790 adhesive layer Substances 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 230000006838 adverse reaction Effects 0.000 description 1
• 230000004520 agglutination Effects 0.000 description 1
• 238000007605 air drying Methods 0.000 description 1
• 108010047495 alanylglycine Proteins 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 150000001340 alkali metals Chemical class 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• 150000001342 alkaline earth metals Chemical class 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• 230000000735 allogeneic effect Effects 0.000 description 1
• KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
• 229940037003 alum Drugs 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
• 239000001099 ammonium carbonate Substances 0.000 description 1
• 229960000723 ampicillin Drugs 0.000 description 1
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000003171 anti-complementary effect Effects 0.000 description 1
• 230000005875 antibody response Effects 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 108010068380 arginylarginine Proteins 0.000 description 1
• 239000012298 atmosphere Substances 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 229940031567 attenuated vaccine Drugs 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
• 239000000688 bacterial toxin Substances 0.000 description 1
• 230000000721 bacterilogical effect Effects 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 239000011324 bead Substances 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
• 229920001222 biopolymer Polymers 0.000 description 1
• 230000007698 birth defect Effects 0.000 description 1
• 101150049515 bla gene Proteins 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 238000010322 bone marrow transplantation Methods 0.000 description 1
• KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
• 239000004327 boric acid Substances 0.000 description 1
• 239000000337 buffer salt Substances 0.000 description 1
• 239000006227 byproduct Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 229940117949 captan Drugs 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 238000005266 casting Methods 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 210000003855 cell nucleus Anatomy 0.000 description 1
• 230000005465 channeling Effects 0.000 description 1
• 229960005091 chloramphenicol Drugs 0.000 description 1
• WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 238000004440 column chromatography Methods 0.000 description 1
• 230000004154 complement system Effects 0.000 description 1
• 238000013329 compounding Methods 0.000 description 1
• 239000000356 contaminant Substances 0.000 description 1
• 238000010411 cooking Methods 0.000 description 1
• 101150054175 cro gene Proteins 0.000 description 1
• 210000004748 cultured cell Anatomy 0.000 description 1
• 238000005520 cutting process Methods 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 210000000805 cytoplasm Anatomy 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• URGJWIFLBWJRMF-JGVFFNPUSA-N ddTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)CC1 URGJWIFLBWJRMF-JGVFFNPUSA-N 0.000 description 1
• 230000002498 deadly effect Effects 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 230000007850 degeneration Effects 0.000 description 1
• 238000007865 diluting Methods 0.000 description 1
• 238000007598 dipping method Methods 0.000 description 1
• 239000006185 dispersion Substances 0.000 description 1
• 239000002612 dispersion medium Substances 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
• 238000001035 drying Methods 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 239000003344 environmental pollutant Substances 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 230000007071 enzymatic hydrolysis Effects 0.000 description 1
• 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
• 238000001704 evaporation Methods 0.000 description 1
• 230000008020 evaporation Effects 0.000 description 1
• 102000013165 exonuclease Human genes 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• 210000003746 feather Anatomy 0.000 description 1
• 210000003754 fetus Anatomy 0.000 description 1
• 239000011152 fibreglass Substances 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 239000012847 fine chemical Substances 0.000 description 1
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
• 238000011010 flushing procedure Methods 0.000 description 1
• 239000011888 foil Substances 0.000 description 1
• 239000000446 fuel Substances 0.000 description 1
• 238000012239 gene modification Methods 0.000 description 1
• 230000005017 genetic modification Effects 0.000 description 1
• 235000013617 genetically modified food Nutrition 0.000 description 1
• 229940049906 glutamate Drugs 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• 150000004676 glycans Chemical class 0.000 description 1
• XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 1
• 108010037850 glycylvaline Proteins 0.000 description 1
• 230000035876 healing Effects 0.000 description 1
• 208000006454 hepatitis Diseases 0.000 description 1
• 231100000283 hepatitis Toxicity 0.000 description 1
• 208000009601 hereditary spherocytosis Diseases 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 235000020256 human milk Nutrition 0.000 description 1
• 210000004251 human milk Anatomy 0.000 description 1
• 230000004727 humoral immunity Effects 0.000 description 1
• 150000004678 hydrides Chemical class 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• 125000001165 hydrophobic group Chemical group 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
• NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
• 230000008076 immune mechanism Effects 0.000 description 1
• 238000003119 immunoblot Methods 0.000 description 1
• 230000001506 immunosuppresive effect Effects 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 229940124589 immunosuppressive drug Drugs 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 230000000415 inactivating effect Effects 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 239000012678 infectious agent Substances 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 230000002147 killing effect Effects 0.000 description 1
• BRHPBVXVOVMTIQ-ZLELNMGESA-N l-leucine l-leucine Chemical compound CC(C)C[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O BRHPBVXVOVMTIQ-ZLELNMGESA-N 0.000 description 1
• 210000000867 larynx Anatomy 0.000 description 1
• 229940070765 laurate Drugs 0.000 description 1
• 239000010410 layer Substances 0.000 description 1
• 229960003136 leucine Drugs 0.000 description 1
• 108010057821 leucylproline Proteins 0.000 description 1
• 230000021633 leukocyte mediated immunity Effects 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• 238000007449 liver function test Methods 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 210000001165 lymph node Anatomy 0.000 description 1
• 239000006166 lysate Substances 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 238000006241 metabolic reaction Methods 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
• 229960004452 methionine Drugs 0.000 description 1
• 230000002906 microbiologic effect Effects 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• QCOXCILKVHKOGO-UHFFFAOYSA-N n-(2-nitramidoethyl)nitramide Chemical compound [O-][N+](=O)NCCN[N+]([O-])=O QCOXCILKVHKOGO-UHFFFAOYSA-N 0.000 description 1
• 210000004897 n-terminal region Anatomy 0.000 description 1
• 230000010807 negative regulation of binding Effects 0.000 description 1
• 230000003472 neutralizing effect Effects 0.000 description 1
• JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 229940049964 oleate Drugs 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 229940039748 oxalate Drugs 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 229940055729 papain Drugs 0.000 description 1
• 235000019834 papain Nutrition 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 239000013610 patient sample Substances 0.000 description 1
• 229940111202 pepsin Drugs 0.000 description 1
• 108010069653 peptide E (adrenal medulla) Proteins 0.000 description 1
• 238000012510 peptide mapping method Methods 0.000 description 1
• 235000020030 perry Nutrition 0.000 description 1
• 210000001539 phagocyte Anatomy 0.000 description 1
• 108010024607 phenylalanylalanine Proteins 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
• 230000003169 placental effect Effects 0.000 description 1
• 238000007747 plating Methods 0.000 description 1
• 231100000719 pollutant Toxicity 0.000 description 1
• 229920001308 poly(aminoacid) Polymers 0.000 description 1
• 108010054442 polyalanine Proteins 0.000 description 1
• 229920000515 polycarbonate Polymers 0.000 description 1
• 239000004417 polycarbonate Substances 0.000 description 1
• 238000012643 polycondensation polymerization Methods 0.000 description 1
• 229920000573 polyethylene Polymers 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 229940085678 polyethylene glycol 8000 Drugs 0.000 description 1
• 235000019446 polyethylene glycol 8000 Nutrition 0.000 description 1
• 238000006116 polymerization reaction Methods 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
• 229920001155 polypropylene Polymers 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
• 230000001323 posttranslational effect Effects 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 230000002250 progressing effect Effects 0.000 description 1
• 229960002429 proline Drugs 0.000 description 1
• 230000000644 propagated effect Effects 0.000 description 1
• 108020001580 protein domains Proteins 0.000 description 1
• 238000000164 protein isolation Methods 0.000 description 1
• 230000009145 protein modification Effects 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• 238000012113 quantitative test Methods 0.000 description 1
• 239000000376 reactant Substances 0.000 description 1
• 230000007420 reactivation Effects 0.000 description 1
• 101150079601 recA gene Proteins 0.000 description 1
• 230000002829 reductive effect Effects 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 230000002787 reinforcement Effects 0.000 description 1
• 230000003014 reinforcing effect Effects 0.000 description 1
• 230000003252 repetitive effect Effects 0.000 description 1
• 230000001718 repressive effect Effects 0.000 description 1
• 230000001850 reproductive effect Effects 0.000 description 1
• 210000001995 reticulocyte Anatomy 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
• 229940043267 rhodamine b Drugs 0.000 description 1
• 201000005404 rubella Diseases 0.000 description 1
• 235000019515 salmon Nutrition 0.000 description 1
• 238000007789 sealing Methods 0.000 description 1
• 238000012031 short term test Methods 0.000 description 1
• 239000010802 sludge Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910000029 sodium carbonate Inorganic materials 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• 239000001488 sodium phosphate Substances 0.000 description 1
• 229910000162 sodium phosphate Inorganic materials 0.000 description 1
• 238000002764 solid phase assay Methods 0.000 description 1
• 238000002798 spectrophotometry method Methods 0.000 description 1
• 229940063673 spermidine Drugs 0.000 description 1
• 210000004988 splenocyte Anatomy 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 239000008174 sterile solution Substances 0.000 description 1
• 238000003756 stirring Methods 0.000 description 1
• 239000011550 stock solution Substances 0.000 description 1
• 239000004575 stone Substances 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 230000008093 supporting effect Effects 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• 238000001308 synthesis method Methods 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 230000009897 systematic effect Effects 0.000 description 1
• 239000008399 tap water Substances 0.000 description 1
• 235000020679 tap water Nutrition 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical group CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 1
• 229960000814 tetanus toxoid Drugs 0.000 description 1
• 229960002180 tetracycline Drugs 0.000 description 1
• 229930101283 tetracycline Natural products 0.000 description 1
• 235000019364 tetracycline Nutrition 0.000 description 1
• 150000003522 tetracyclines Chemical class 0.000 description 1
• 238000004809 thin layer chromatography Methods 0.000 description 1
• 125000003396 thiol group Chemical group [H]S* 0.000 description 1
• 229940104230 thymidine Drugs 0.000 description 1
• 210000001541 thymus gland Anatomy 0.000 description 1
• 229960002175 thyroglobulin Drugs 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 108700012359 toxins Proteins 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• AIJAJGQAPNYWOW-UHFFFAOYSA-N tris(3-nitrophenyl) phosphate Chemical compound [O-][N+](=O)C1=CC=CC(OP(=O)(OC=2C=C(C=CC=2)[N+]([O-])=O)OC=2C=C(C=CC=2)[N+]([O-])=O)=C1 AIJAJGQAPNYWOW-UHFFFAOYSA-N 0.000 description 1
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
• 201000008297 typhoid fever Diseases 0.000 description 1
• 238000002604 ultrasonography Methods 0.000 description 1
• 241000701161 unidentified adenovirus Species 0.000 description 1
• 241001515965 unidentified phage Species 0.000 description 1
• 239000012646 vaccine adjuvant Substances 0.000 description 1
• 229940124931 vaccine adjuvant Drugs 0.000 description 1
• 229940125575 vaccine candidate Drugs 0.000 description 1
• 229940070710 valerate Drugs 0.000 description 1
• NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• IBIDRSSEHFLGSD-UHFFFAOYSA-N valinyl-arginine Natural products CC(C)C(N)C(=O)NC(C(O)=O)CCCN=C(N)N IBIDRSSEHFLGSD-UHFFFAOYSA-N 0.000 description 1
• 231100000216 vascular lesion Toxicity 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1